Igc pharma expands calma alzheimer's phase 2 trial with prestigious research site at butler hospital's memory and aging program

Potomac, maryland / access newswire / april 8, 2025 / igc pharma, inc. (nyse american:igc) ("igc pharma" or the "company") today announced the expansion of its ongoing phase 2 calma clinical trial with the addition of butler hospital's memory and aging program, a nationally recognized research center affiliated with the warren alpert medical school of brown university, in providence, rhode island. the site will support enrollment for the calma study evaluating igc-ad1, igc pharma's investigational therapy for agitation in alzheimer's disease, a condition affecting a majority of alzheimer's patients and significantly impacting caregivers.
IGC Ratings Summary
IGC Quant Ranking